



# Corporate Information

## Corporate Overview

<b>Corporate name</b>	Torii Pharmaceutical Co., Ltd.
<b>Established</b>	November 1, 1921
<b>Paid-in capital</b>	¥5,190 million
<b>Business line</b>	Manufacturing and marketing of pharmaceutical products
<b>Number of employees</b>	560 (as of December 31, 2021)
<b>Stock exchange listing</b>	The Prime Market of the Tokyo Stock Exchange (Securities code: 4551)
<b>Head office</b>	4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo 103-8439, Japan Telephone: +81-3-3231-6811




## Corporate Data




### Net sales by disease area

	(Millions of Yen)	
	FY2020	FY2021
<b>Net sales</b>	41,700	<b>46,987</b>
Sales of products	41,053	<b>46,290</b>
Renal diseases and hemodialysis	14,773	<b>13,502</b>
Skin diseases	9,918	<b>11,992</b>
Allergens	11,332	<b>15,971</b>
Other	5,029	<b>4,824</b>
Other sales	647	<b>697</b>


### Net Sales



### Operating Income



### Net Income



## Mainstay Products (as of December 31, 2021)

### Riona Tablets Therapeutic agent for hyperphosphatemia/ Therapeutic drug for iron deficiency anemia (IDA)



Riona is a medication that treats hyperphosphatemia in patients with chronic kidney disease, including hemodialysis, peritoneal dialysis, and non-dialysis chronic kidney disease patients. Approval for an additional indication of iron deficiency anemia (IDA) was received in March 2021.

### REMITCH Oral antipruritic agent



REMITCH is a treatment for pruritus in patients on dialysis and with chronic liver disease for which conventional antipruritic medications are ineffective.

### CORECTIM Topical Janus kinase (JAK) inhibitor



CORECTIM<sup>®</sup> Ointment is the world's first topical JAK inhibitor for treatment of atopic dermatitis that suppresses the overactivation of immune responses by inhibiting the action of JAKs, which play key roles in immune activation signaling in cells.

### ANTEBATE Topical corticosteroid



ANTEBATE is a treatment that improves the symptoms in patients with skin diseases, such as atopic dermatitis and contact dermatitis, by suppressing inflammation.

### CEDARCURE Japanese Cedar Pollen Sublingual Tablets Japanese cedar pollinosis (allergen immunotherapy)



CEDARCURE is a sublingual allergen immunotherapy drug for Japanese cedar pollinosis. This fast-dissolving sublingual tablet was the first of its kind available in Japan for adult and pediatric patients.

### MITICURE House Dust Mite Sublingual Tablets House dust mite allergy (allergen immunotherapy)



MITICURE is an allergen immunotherapy tablet for house dust mite-induced allergic rhinitis. Additional dosage and administration of this drug for pediatric indication was approved in February 2018.